

REMARKS/ARGUMENTS

Response to Notice of Missing Parts

Applicants submit that the computer readable form (CRF) of the sequence listing for the instant application will be identical to the CRF sequence listing filed for parent Application No. 09/580,018, filed May 26, 2000. In accordance with 37 C.F.R. § 1.821(e), please use the CRF substitute sequence listing filed for Application No. 09/580,018 as the CRF sequence listing for the instant application. The information contained in the computer readable disk of Application No. 09/580,018 was prepared through the use of the software program "PatentIn".

It is understood that the U.S. Patent and Trademark Office will make the necessary change in the application number and filing date for the computer readable form that will be used for the instant application. The paper copy of the sequence listing filed for parent Application No. 09/580,018, which is identical to the CRF substitute sequence listing for Application No. 09/580,018, is incorporated into the substitute specification, enclosed herewith, on pages 114-137. This amendment contains no new matter.

Amendments to the Specification

Applicants enclose marked-up and clean copies of a substitute specification in accordance with 37 C.F.R. 1.125(b) in Appendices A and B, respectively. The amendments incorporated into the substitute specification add paragraph numbering, italicize species names, conform the specification to the sequence listing and drawings, and add information concerning the ATCC deposit information for antibodies 10D5 and 3D6.


Specifically, in the substitute specification enclosed herewith, paragraphs [0079], [0081] and [0264] have been amended to italicize species names. Paragraph [0031] describes Figure 10; and to conform with the amendment to Figure 10; the paragraph has been amended to identify the upper and lower panels of Figure 10 as Figure 10A and 10B, respectively. Paragraph [0036] describes Figure 15. The paragraph has been amended and supplemented with five replacement paragraphs, [0037]-[0041], to describe Figures 15A-15E, 15A, 15B, 15C, 15D, and

DALE B. SCHENK
Appl. No. 10/777,792
First Preliminary Amendment dated August 19, 2004

15E, respectively. Paragraph [0327] has also been amended to identify Figures 15A-15E. Paragraphs [0322] and [0325] have been amended to conform the alum concentration to the alum concentration recited in Figure 15 as filed in Application No. 09/201,430, filed November 30, 1998, which is incorporated herein by reference. ATCC deposit information for antibodies 10D5 and 3D6 have been added to paragraphs [0291], [0344], and [0419]. Additionally, the sequence listing has been added to the end of the specification. As these amendments contain no new matter, the substitute specification contains no new matter as well.

Applicants deposited the cell line producing the antibody 10D5 and the cell line producing the antibody 3D6 with the ATCC on April 8, 2003. Applicants submit a statement under MPEP § 2406.02 herewith. The cell lines deposited with the ATCC are the cell lines producing the antibodies 10D5 and 3D6, respectively, which are identified in the instant specification and in Application No. 09/201,430, filed November 30, 1998 on page 58, line 6, and in Application No. 60/080,970, filed April 7, 1998, on page 32, line 23. Applicants have amended paragraphs [0291], [0344], and [0419] of the substitute specification to recite the depository, accession number, and deposit date of the cell lines producing the 10D5 and 3D6 antibodies, respectively. These amendments do not add new matter (*see In re Lundak*, 227 USPQ 90 (Fed. Cir. 1985) and MPEP § 2406.01).

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:adm
60286521 v1